Patents Represented by Attorney, Agent or Law Firm Kathryn A. Anderson
-
Patent number: 5767065Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.Type: GrantFiled: June 6, 1995Date of Patent: June 16, 1998Assignee: Immunex CorporationInventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
-
Patent number: 5763223Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.Type: GrantFiled: June 25, 1996Date of Patent: June 9, 1998Assignee: Immunex CorporationInventors: Steven R. Wiley, Raymond G. Goodwin
-
Patent number: 5753203Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides and oligomers find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: December 20, 1995Date of Patent: May 19, 1998Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Patent number: 5738844Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.Type: GrantFiled: May 30, 1995Date of Patent: April 14, 1998Assignee: Immunex CorporationInventors: M. Patricia Beckmann, Douglas P. Cerretti
-
Patent number: 5728813Abstract: Antibodies to elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.Type: GrantFiled: November 12, 1996Date of Patent: March 17, 1998Assignee: Immunex CorporationInventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
-
Patent number: 5677430Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: December 12, 1995Date of Patent: October 14, 1997Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Patent number: 5674704Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.Type: GrantFiled: May 6, 1994Date of Patent: October 7, 1997Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
-
Patent number: 5670625Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.Type: GrantFiled: June 2, 1995Date of Patent: September 23, 1997Assignee: Immunex CorporationInventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
-
Patent number: 5627267Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.Type: GrantFiled: June 1, 1995Date of Patent: May 6, 1997Assignee: Immunex CorporationInventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum
-
Patent number: 5576191Abstract: ST2 ligand polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing ST2 ligand polypeptides. The ST2 ligand polypeptide binds to a receptor that is expressed on cell types that include certain Hodgkin's Disease-derived tumor cells.Type: GrantFiled: June 17, 1994Date of Patent: November 19, 1996Assignee: Immunex CorporationInventors: Margit Gayle, Jennifer L. Slack, Hans-Juergen Gruss, John E. Sims, Steven K. Dower
-
Patent number: 5543320Abstract: Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, antibodies to mammalian Interleukin 7 receptors and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.Type: GrantFiled: June 25, 1993Date of Patent: August 6, 1996Assignee: Immunex CorporationInventors: Linda S. Park, Raymond G. Goodwin
-
Patent number: 5538863Abstract: A novel strain of Saccharomyces cerevisiae is useful as a host cell in the production of recombinant proteins. The novel S. cerevisiae cells transformed with a recombinant expression vector encoding a desired heterologous protein, preferably fused to a suitable N-terminal signal peptide, are cultivated under conditions that promote expression of the protein. Also provided are signal peptides derived by replacing the native signal peptidase cleavage site of a type I interleukin-1 receptor signal peptide with the tripeptide AlaXAla, wherein X represents an amino acid selected from Leu, Phe, and Gln. An expression system comprises a yeast host cell (preferably the novel S. cerevisiae strain) transformed with an expression vector comprising a promoter functional in yeast cells operably linked to DNA encoding the novel signal peptide, which is fused to the N-terminus of DNA encoding a desired heterologous protein.Type: GrantFiled: July 1, 1993Date of Patent: July 23, 1996Assignee: Immunex CorporationInventor: Virginia L. Price
-
Patent number: 5516658Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.Type: GrantFiled: May 9, 1994Date of Patent: May 14, 1996Assignee: Immunex CorporationInventors: M. Patricia Beckmann, Douglas P. Cerretti
-
Patent number: 5512457Abstract: elk ligand (elk-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing elk-L polypeptides. The elk-L polypeptide binds to a cell surface receptor that is a member of the tyrosine kinase receptor family.Type: GrantFiled: March 15, 1994Date of Patent: April 30, 1996Assignee: Immunex CorporationInventors: Stewart Lyman, M. Patricia Beckmann, Peter R. Baum, Melissa K. Carpenter
-
Patent number: 5480981Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: April 12, 1994Date of Patent: January 2, 1996Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Patent number: 5447860Abstract: A novel receptor protein tyrosine kinase named ork (orphan receptor tyrosine kinase) is identified and characterized. cDNA encoding the ork protein is inserted into an expression vector for production of the protein via recombinant DNA technology. The ork cDNA, when transfected into Cos-7 cells, encodes a 140 Kd protein with in vitro kinase activity. The ork gene is expressed predominantly in placenta and lung, with lower levels in umbilical vein endothelial cells, brain and kidney.Type: GrantFiled: October 14, 1994Date of Patent: September 5, 1995Assignee: Immunex CorporationInventor: Steven F. Ziegler
-
Patent number: 5420247Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed.Type: GrantFiled: September 10, 1993Date of Patent: May 30, 1995Assignee: Immunex CorporationInventors: David P. Gearing, Patricia M. Beckmann